Listen on the go
CORRECT!
Next question
Faculty & Disclosures
Dr Wanda Phipatanakul

Boston Children’s Hospital, Harvard, MA, USA

Wanda Phipatanakul is the director of the Division of Immunology Research Center at Boston Children’s Hospital and Westonian endowed professor of paediatrics at Harvard Medical School. read more

Dr Phipatanakul conducts both school- and home-based asthma studies in children and has had continuous National Institutes of Health (NIH) funding for 20 years. She leads the National Institute of Allergy and Infectious Diseases (NIAID) School Inner-City Asthma Intervention Study; the National Heart, Lung, and Blood Institute (NHLBI) Environment Assessment of Sleep in Youth; the NIAID-funded PARK study evaluating omalizumab in preventing the atopic march and asthma; and a NIAID IDEA study evaluating the response to dupilumab in patients carrying the Interleukin (IL)-4 receptor alpha R576 gene variant. She leads her centre as paediatric principal investigator in multiple NHLBI asthma and prevention networks, including the Severe Asthma Research Program, the Precise Severe Asthma Network, the Atopic Dermatitis Research Network and the Childhood Asthma in Urban Settings Network.

She has authored over 300 publications in scientific journals, including JAMA and the New England Journal of Medicine. She serves on the board of directors of the American Academy of Allergy, Asthma, and Immunology and the American Board of Allergy and Immunology. She also serves as associate editor for the Journal of Allergy and Clinical Immunology (JACI) and on the editorial board for several other journals including JACI: in Practice and Chest.

Dr Wanda Phipatanakul discloses: Advisory board or panel fees from AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals and Sanofi.
Dr Ioanna Tsiligianni

University of Crete, Crete, Greece

Ioanna Tsiligianni is an associate professor in general practice and public health, in the Department of Social Medicine, Faculty of Medicine, University of Crete. She is the past president (2018–2020) of the International Primary Care Respiratory Group (IPCRG). read more

Dr Tsiligianni’s research centres mainly on public health and primary care issues, with a special focus on primary care respiratory medicine, chronic obstructive pulmonary disease (COPD), asthma and lung cancer.

Ioanna Tsiligianni was chair of the IPCRG World Conference in 2014, and coordinated the development of the first national guidelines for primary care in COPD and asthma in Greece. She is the editor-in-chief of Primary Care Respiratory Medicine. 

She is an active member of several organizations, including the European Rural and Isolated Practitioners Association (EURIPA), the International Institute of Compassionate Care and the European Respiratory Society (ERS).

She has more than 170 publications and she is the recipient of 17 awards at international and national level.

Dr Ioanna Tsiligianni discloses: Advisory board or panel fees from Boehringer Ingelheim (relationship terminated) and Novartis (relationship terminated). Grants/Research Support from AstraZeneca (relationship terminated) and GlaxoSmithKline (relationship terminated).
Dr Atul Gupta

King’s College Hospital, London, UK

Atul Gupta is a senior paediatric respiratory consultant at King’s College Hospital & King’s College London. read more

Dr Gupta is head of the department and specializes in all areas of paediatric respiratory medicine, including severe asthma. His research interests centre on asthma, airway disease and respiratory infections. He has published over 175 papers on a range of respiratory-related conditions.

Dr Gupta has received the Lorber Prize, awarded by the Royal College Of Paediatrics and Child Health; The James Fellowship, awarded by the British Medical Association; VASR Memorial Gold Medal; and S.S Manchanda Research Gold Medal.

Dr Atul Gupta discloses: Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis Pharmaceuticals. Grants/research support from Airosnett, Boehringer Ingelheim, GlaxoSmithKline and Novartis Pharmaceuticals.
Ms Viv Marsh

Dudley Respiratory Group, West Midlands, UK

Viv Marsh qualified as a registered general nurse (RGN) in 1991 and as a registered sick children’s nurse (RSCN) in 1993, and since then has worked in acute paediatrics, school nursing, specialist nursing and clinical education. read more

In her current National Health Service (NHS) role, Ms Marsh works with the Dudley Respiratory Group supporting the development of integrated services and standards for paediatric asthma care. As the clinical lead for Children and Young People’s Asthma Transformation, she is responsible for the implementation and delivery of the national bundle of asthma care across the Black Country, West Midlands. In her role as the facilitation coordinator for the IMP²ART Trial, she works with the research team and general practitioner practices to deliver the implementation strategy to improve supported self-management of asthma.

Ms Marsh sits on the committee for the National Paediatric Respiratory and Allergy Nurses Group (NPRANG), and is a member of the Primary Care Respiratory Society’s Education Committee.

Ms Viv Marsh discloses: Advisory board or panel fees from Allergy Therapeutics. Speaker’s bureau fees from Napp Pharmaceuticals
Ms Monique Cooper

Miami, FL, USA

Monique Cooper is a parent advocate to those who have children with asthma, attention deficit hyperactivity disorder (ADHD) and anxiety. read more

Monique is co-author of a children’s book series about her son’s disabilities. She co-founded the Javan Allison Foundation after gaining certification to bring awareness to mental health and anxiety, and she is the founder of Success Starts with Me, a mentoring programme for children. Monique continues to tackle several projects empowering children like her son, Javan, who suffer from the three As (asthma, anxiety and ADHD).

Because of her great work in the community, Monique has been honoured by the city of Miami Gardens as one of the “Ordinary Women, doing Extraordinary Things”.

Ms Monique Cooper has no interests/relationships or affiliations to disclose in relation to this activity.
touchIMMUNOLOGY touchIMMUNOLOGY

Advances in the management of severe paediatric asthma

Watch a conversation among experts and multidisciplinary discussions covering best practices and the latest developments in the diagnosis, treatment and long-term management of children with severe asthma.

Curriculum Activities

Respiratory Disorders, Allergic Conditions
Watch Time: 49 mins
touchMDT
Management of severe paediatric asthma: From hospital to home
CE/CME ACCREDITED Ms Monique Cooper, Dr Atul Gupta, Ms Viv Marsh, Dr Wanda Phipatanakul, Dr Ioanna Tsiligianni

Members of the MDT and a patient advocate discuss the optimal management of severe asthma in children

Learning objectives
Learning Objectives
  • Recall the diagnostic workup for severe type 2 asthma in children
  • Explain the pathophysiology of severe type 2 asthma and how this can guide treatment decisions
  • Discuss the importance of the MDT in optimizing the management of children with severe asthma
Respiratory Disorders, Allergic Conditions
Watch Time: 34 mins
touchIN CONVERSATION
Improving outcomes in severe paediatric asthma: New treatments, new possibilities
CE/CME ACCREDITED

Watch an asthma expert and a primary care respiratory specialist discuss diagnosis, treatment and management of severe asthma in children.

Learning objectives
Learning Objectives
  • Recall the symptoms associated with severe asthma in children
  • Summarize the clinical evidence supporting the use of biologics in children with severe asthma
  • Describe the optimal long-term management of children with severe asthma

Other Curriculum Activities

Learn more with a series of activities which are linked and developed as a curriculum

Allergic Conditions
touchCURRICULUM
Eosinophilic oesophagitis
 CME ACCREDITED

Watch interviews and expert perspectives covering progress elucidating the underlying pathophysiology of EoE and how this informs the development of new therapeutic approaches with the potential to reduce the burden of disease among patients with EoE.

Including:

touchCONGRESS

Improving outcomes for patients with eosinophilic oesophagitis: What do the data from AAAAI 2022 tell us?

touchMDT

Exploring eosinophilic oesophagitis: How can multidisciplinary management improve outcomes?

touchPANEL DISCUSSION

The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options

touchEXPERT OPINIONS

What’s new for eosinophilic oesophagitis? A case-based discussion of patient care

Allergic Conditions
Curriculum Inclusions:
  • Describe the complex pathophysiology and manifestations in children and adults
  • Outline the chronic nature of EoE and implications for disease management
  • Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE
IME
CME activities are developed by touchIME for touchIMMUNOLOGY.

All touchIME CME activities are accredited. Learners can claim ACCME credits upon completion of the activities. This content is for healthcare professionals only.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72